Agenus | AGEN - Interest Expense On Debt


Agenus reported $16.02M in Interest Expense on Debt for its fiscal quarter ending in December of 2025.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Agenus USD 16.02M 2.85M Dec/2025
Amgen USD 657M 4M Mar/2026
AstraZeneca USD 484M 181M Dec/2025
Bristol-Myers Squibb USD 411M 21M Mar/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 240M 15M Mar/2026
GlaxoSmithKline GBP 167M 21M Mar/2026
Glaxosmithkline GBP 177.95M 6.05M Sep/2025
Incyte USD 569K 13K Mar/2026
Intrexon USD 2K 5K Jun/2024
J&J USD 43M 25M Mar/2026
Jiangsu Hengrui CNY 254.59M 253.85M Sep/2025
Karyopharm Therapeutics USD 12.62M 1.24M Dec/2025
MacroGenics USD 3.34M 2.54M Sep/2025
Merck EUR 104M 17M Mar/2026
Merck USD 479M 67M Mar/2026
Northwest Biotherapeutics USD 1.52M 276K Mar/2024
Novartis USD 343M 39M Mar/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 671M 40M Mar/2026
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Rigel Pharmaceuticals USD 2.06M 31K Sep/2024
Sangamo BioSciences 97.56M 11.39M Jun/2025
Veracyte USD 2K 1000 Dec/2023